Results of Operations and Financial Condition
Show detailsHide details
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Ligand Pharmaceuticals Incorporated
Could not find a ticker for this position, may be a filing error
A biopharmaceutical company that licenses drug technologies and collects royalties on medicines its partners develop and sell. Its best-known asset is Captisol, a sugar-based "cage" that wraps around hard-to-dissolve drugs to make them stable and deliverable. Founded in 1987 as Progenx, Inc., it was renamed Ligand Pharmaceuticals in 1989 after the biochemistry term for a molecule that binds to a receptor — a nod to its original focus on receptor biology.
0.75% Convertible Senior Notes due 2023
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 2.01 Completion of Acquisition or Disposition of Assets · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 3.02 Unregistered Sales of Equity Securities · 8.01 Other Events · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 8.01 Other Events · 9.01 Financial Statements and Exhibits
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders
1.01 Entry into a Material Definitive Agreement · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
1.02 Termination of a Material Definitive Agreement